Global medical device company Mauna Kea Technologies ended its 2015 fiscal year with a 22 percent decline from its 2014 sales. "Following our announcement on October 8 of the company's intent to modify its commercialization strategy, we anticipated a dilution of sales productivity as the global leadership team and regional sales leaders worked to implement our new strategy,” said Sacha Loiseau, founder and CEO of Mauna Kea. Sales in the Americas declined by 10 percent, with Mauna Kea citing the absence of sales in Brazil and its sluggish economy, compounded by a general slowdown of public funding. North American sales rose by 14 percent, while Asian-Pacific sales declined by 35 percent as a result of the delay in obtaining regulatory approval for the Cellvizio 100 microscopy system in China. Sales in Europe, the Middle East and Africa dropped 23 percent. Mauna Kea Technologies is a global medical device company focused on endomicroscopy and tissue characterization.